Alexis Rivera Flores’ Post

Getting ready to Bio International Convention @ San Diego !!!! Why Puerto Rico for Bioscience Pharma Expansion? 1. Robust R&D Ecosystem: From the groundbreaking work being undertaken at the Molecular Science Research Center (MSRC) to advanced clinical trials conducted by the Puerto Rico Consortium for Clinical Investigation (PRCCI), Puerto Rico is a powerhouse of innovation. 2. State-of-the-Art Manufacturing Capabilities: Puerto Rico’s capabilities extend to sophisticated processes including fill & finish for vials, syringes, and combo products, not to mention advanced bio products testing and lyophilization. 3. Exceptional Local Workforce: Puerto Rico boasts the highest concentration of pharmaceutical and medical device professionals in the U.S., ensuring expert handling and innovation at every stage of production. 4. Smart Tax Incentives: Benefit from up to 50% tax credits for R&D expenditures and some of the most competitive incentives in the U.S., enhancing the financial viability of your biotech projects. Contact us to schedule a meeting: https://lnkd.in/ef5jphsc

This morning EuropaBio - the European Association for Bioindustries co-hosted a roundtable discussion with MEP Fulvio Martusciello. The discussion with key stakeholders from the healthcare biotechnology ecosystem, guided by the recently published Charles River Associates study, covered how the GPL will impact the innovation ecosystem and what remains crucial to keep in mind going into the upcoming election cycle and beyond. Some key takeaways from the discussion include: 🔵 Predictability remains of critical importance to retaining the innovative companies that are Europe's strongest asset. 🔵 A baseline of incentives is necessary to foster a dynamic market in which smaller companies can align with the innovation cycle while maintaining their competitiveness. 🔵 Simplifying the regulatory processes to ensure that medicinal products arrive on the market as fast as possible for patients. ➡ Read more https://lnkd.in/eHZMiaHU

✨ We are pleased to announce that Piotr Garstecki will represent Scope Fluidics at the PHASE - Polish Healthcare Assets Sector Event Conference, which is the largest discussion on Polish biotechnology. 🔹 The PHASE - Polish Healthcare Assets Sector Event Conference is aimed at all those interested in medical biotechnology, including: ▪ Capital market participants  ▪ Representatives of public institutions  ▪ Entrepreneurs  ▪ Scientists 🔹 The PHASE - Polish Healthcare Assets Sector Event will be held on August 27-29, 2024. ◾ Two days and more than a dozen panels in five main thematic blocks: Economy, Investment, Business, Technology, Science. The third day will be dedicated to investor presentations of companies. ◾ Presentation of the report of the Polish Union of Innovative Medical Biotechnology Companies BioInMed "Impact of the medical biotechnology sector on the Polish economy and medical progress". 🌍 www - https://lnkd.in/dpj26xHs #PHASE2024 #biotechnology #scopefluidics #biotech

🔊 🔊 Register now for Positioning Ireland for Success - Fuelling Innovation for the Future of Irish Biopharma, hosted by the Royal Irish Academy, in partnership with SSPC, SFI Research Centre for Pharmaceuticals and BioPharmaChem Ireland. This event will serve as a platform for stakeholders to engage in discussions on the strategic measures required to support the sector's evolution. https://lnkd.in/enFEyybk 💡 💡 Join Pat Guiry, President, Royal Irish Academy; Danny McCoy, CEO, Ibec; Prof Damien Thompson, Professor of Molecular Modelling, UL & Director, SSPC, along with a number of confirmed speakers from across the ecosystem. The Irish biopharma sector is poised for significant growth by 2030, requiring robust innovation ecosystems for sustained competitiveness. Third-level research investment is crucial, with universities and research institutions serving as vital innovation hubs. Sustainable funding mechanisms are essential for long-term R&D growth and global competitiveness with industry-academic collaboration emphasised to position Ireland as a global biopharma leader and attract international investments. Panels covering: ✅ Panel 1: Positive policies to fuel innovation for the future of Irish biopharma ✅ Panel 2: The transformative effects of digital technologies on skill sets, advanced manufacturing, and the research landscape. ✅ Panel 3: Empowering sustainability: Third-Level research, EU Regulations, and academic-industry collaboration in the biopharma sector's 2030 ecosystem  

The scientific community is abuzz with the development of groundbreaking bioproducts that leverage biological resources and processes. This has sparked the growth of a bioeconomy - a new, rapidly expanding sector contributing significantly to the global economy through a range of products, processes, tools, and services derived from biological sources. This sector covers a wide array of products including pharmaceuticals, food, fuels, and consumer goods, all of which depend on biological organisms at some point in their development cycle. Biomanufacturing plays a crucial role in scaling these innovative bioproducts to a commercial level. However, this field has faced challenges in keeping pace with development, primarily due to limited production capabilities and a shortage of skilled professionals in biomanufacturing. This gap became more apparent during the COVID pandemic, highlighting the urgent need for development in this area. Chrysea's latest acquisition is strategically aimed at overcoming these obstacles by enhancing development capacities and accelerating the commercialization of new products and solutions. Central to this strategy is the advancement of specialized biomanufacturing processes. https://lnkd.in/djhFRfQS

"The Future of 𝑳𝒂𝒃𝒐𝒓𝒂𝒕𝒐𝒓𝒚 𝑴𝒊𝒙𝒆𝒓𝒔: Trends and Innovations" ➤ 𝑪𝒍𝒊𝒄𝒌 𝑯𝒆𝒓𝒆 𝒕𝒐 𝑮𝒆𝒕 𝑷𝑫𝑭: https://lnkd.in/dE-8qR5h #Laboratorymixers are used in research laboratories to mix different ingredients or components to get a #homogeneous mixture. The most common type of laboratory mixers are #vortexmixers, #magneticstirrers, and shakers. Laboratory mixers are designed for blending, mixing, kneading, and other #applications involving the physical processing of many ingredients or components. Increasing funding and investment in the #pharmaceuticalindustry, including biotechnology, #medicaldevices, and #diagnostics, is critical for driving innovation, advancing #research and development, and improving patient outcomes. This investment comes from various sources, such as governments, associations, and private funding from venture capitalists, which has led to the significant growth of the sector. ➤ 𝑫𝒊𝒗𝒆𝒓𝒔: 1. Increasing Funding & Investment in the #Pharmaceutical, #Biotechnology, & Life Science Industries for Fostering Innovations            2. Funding to Support R&D         3. Rising Prevalence of Chronic #Diseases Emphasizing the Need for Developing Novel Therapies            4. Expansion of Diagnostic and #Pathology Laboratories Enhancing the Clinical Capabilities ➤ 𝑲𝒆𝒚 𝑷𝒍𝒂𝒚𝒆𝒓𝒔: Thermo Fisher Scientific Inc. (U.S.), Eppendorf SE (Germany), Bio-Rad Laboratories, Inc. (U.S.), IKA-Werke (Germany), Benchmark Scientific Inc. (U.S.), Cole-Parmer Instrument Company (U.S.) #LaboratoryMarket #LabEquipment #ScientificResearch #LabTech #LabSupplies #LabInnovation #ScientificInstruments #LabSolutions #ResearchTools #LabIndustry #BiotechMarket #LabTechnology #ScientificMarket #LabTrends #AnalyticalInstruments #LaboratoryScience #ScientificEquipment #ResearchEquipment

#ICYMI our Chief Development Officer, Gilles Gallant, BPharm PhD FOPQ, joined industry leaders for Citeline Commercial’s roundtable at #BIO2024 exploring strategic practices, nuanced needs and key lessons for #biotech companies to consider when conducting #clinicaltrials.     Below, Dr. Gallant shares his insights on the value of diversifying clinical trials globally and maintaining a small, agile team to enhance operational efficacy and research outcomes. Check out additional highlights from the roundtable: https://bit.ly/4cmfzdw Biotechnology Innovation Organization

📢 World Leaders Discuss Europe's Cluster Policy for Green Digital and Biotech Transitions 💥 More than 900 experts from clusters and the EU Commission gathered in Brussels for the European Cluster Conference. They discussed cluster policy needed for Europe to become a world leader in green and digital transitions and biotechnology. 🌍💪🏼 Compared to the US and China, EU biotech clusters lack support in funding, resources, and scaling up bioproduction. The European Federation of Pharmaceutical Industries and Associations suggested focusing resources in a few large clusters. However, some experts emphasized the importance of networking and mapping existing expertise in topic-specific metaclusters. 🌐🔬 Jan-Philippe Kramer, from the European Cluster Collaboration Platform, presented Innovation scores, showing that China has caught up with the EU in terms of innovation. Clusters play a crucial role in the innovation process, but their sector-specific needs must be better understood and heard. 👩💼💻💡 #BioprocessUpdates #EuropeanClusterConference #clusterpolicy #greentransitions #digitaltransitions #biotechnology #EUbiotechclusters #funding #resources #scalingup #bioproduction #networking #metaclusters #innovation #sectorspecific #EU ▷ Read the full article here: 📎 https://lnkd.in/d6qjD5ce

SFBN Feed: Peninsula biotech to cut 40% of staff as it awaits analysis of halted clinical trial https://lnkd.in/gTXPXt3X The company has lost more than half a billion dollars over nine years. Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks #BayArea #SanFrancisco #Biotech #Lifescience #News

The scientific community is abuzz with the development of groundbreaking bioproducts that leverage biological resources and processes. This has sparked the growth of a bioeconomy - a new, rapidly expanding sector contributing significantly to the global economy through a range of products, processes, tools, and services derived from biological sources. This sector covers a wide array of products including pharmaceuticals, food, fuels, and consumer goods, all of which depend on biological organisms at some point in their development cycle. Biomanufacturing plays a crucial role in scaling these innovative bioproducts to a commercial level. However, this field has faced challenges in keeping pace with development, primarily due to limited production capabilities and a shortage of skilled professionals in biomanufacturing. This gap became more apparent during the COVID pandemic, highlighting the urgent need for development in this area. Chrysea's latest acquisition is strategically aimed at overcoming these obstacles by enhancing development capacities and accelerating the commercialization of new products and solutions. Central to this strategy is the advancement of specialized biomanufacturing processes.